Table 2 Baseline information of patients
From: Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma
Characteristic | Patients | Neoadjuvant chemotherapy | Non-neoadjuvant chemotherapy |
|---|---|---|---|
Number | 89 | 75 (84.3%) | 14 (15.7%) |
Gender | |||
Male | 46 | 40 (87%) | 6 (13%) |
Female | 43 | 35 (81.4%) | 8 (18.6%) |
Age | |||
<25 years old | 30 | 25 (83.3%) | 5 (16.7%) |
≥25 years old | 59 | 50 (84.7%) | 9 (15.3%) |
Tumor size | |||
≤5 cm | 35 | 30 (85.7%) | 5 (14.3%) |
>5 cm | 54 | 45 (83.3%) | 9 (16.7%) |
Primary tumor site | |||
Limb | |||
Upper limb | 23 | 20 (87%) | 3 (13%) |
Lower limbs | 52 | 43 (82.7%) | 9 (17.3%) |
Trunk | 14 | 12 (85.7%) | 2 (14.3%) |
Shoulder-back | 8 | 6 (75.0%) | 2 (25.0%) |
Hip | 2 | 2 (100%) | 0 |
Chest wall | 2 | 2 (100%) | 0 |
Pelvis | 1 | 1 (100%) | 0 |
Neck | 1 | 1 (100%) | 0 |
Pathological pattern | |||
Unipolar type | 41 | 31 (75.6%) | 10 (24.4%) |
Bipolar type | 28 | 26 (92.8%) | 2 (7.2%) |
Undifferentiated type | 8 | 8 (100%) | 0 (0%) |
Unknown | 12 | 10 (83.3%) | 2 (16.7%) |
Enneking staging | |||
Phase IIA | 41 | 33 (80.4%) | 8 (19.6%) |
Phase IIB | 48 | 42 (87.5%) | 6 (12.5%) |
AJCC staging | |||
Phase II | 35 | 30 (85.7%) | 5 (14.3%) |
Phase III | 54 | 45 (83.3%) | 9 (16.7%) |
Chemotherapy course | |||
<6 | 39 | ||
≥6 | 45 | ||
No | 5 | ||
Surgical method | |||
Amputation | 8 | 8 (100%) | 0 (0%) |
Extended resection | 81 | 67 (%) | 14 (%) |
Surgical margin | |||
Positive | 3 | 3 (100%) | 0 (0%) |
Negative | 86 | 72 (83.7%) | 14 (16.3%) |
The 1st visiting hospital | |||
Our hospital | 20 | 17 (85%) | 3 (15%) |
Other hospital | 69 | 58 (84.1%) | 11 (15.9%) |
Local recurrence | |||
Yes | 20 | 17 (85%) | 3 (15%) |
No | 69 | 58 (84.1%) | 11 (15.9%) |
Distant metastasis | |||
Yes | 17 | 12 (70.6%) | 5 (29.4%) |
No | 72 | 63 (87.5%) | 9 (12.5%) |
Last follow-up state | |||
Died from disease | 16 | 11 (68.7%) | 5 (31.3%) |
Died from other reasons | 1 | 0 (0%) | 1 (100%) |
Survived | 72 | 64 (88.8%) | 8 (11.2%) |